gip glp 1 agonist tirzepatide Unveiling Tirzepatide's Therapeutic Spectrum: A Dual GIP/GLP-1 Targeting Metabolic, Neurological, and Cardiovascular Health The B12 Store Pembroke Pines

In the phase 2 study of type-2 diabetic patients, Tirzepatide produced a profound reduction in body weight and improved HbA1c levels, both of which were superior relative to effects of Dulaglutide in the active comparator arm [939], thus demonstrating the translation of the preclinical observations

Jolliet, Lausanne (Mdecine intensive)

Do Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Cause Heart Failure

With a sharp focus on metabolic diseases, the company is poised to lead the booming obesity market

In their article, the researchers detail how these medications can both directly and indirectly reduce liver fat, inflammation, and fibrosis, potentially improving disease outcomes

Allingbjerg, M.-L., Hansen, S